XNASMIRA
Market cap20mUSD
Jan 10, Last price
1.26USD
1D
-5.26%
1Q
15.60%
IPO
-79.03%
Name
Mira Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L+69.77%
CFO
-6m
L+0.49%
Profile
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 17,052 | 5,344 | ||
Unusual Expense (Income) | ||||
NOPBT | (17,052) | (5,344) | ||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | (17,052) | (5,344) | ||
Net income | (11,982) 69.77% | (7,058) 224.29% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 7,704 | 2,904 | ||
BB yield | -39.52% | |||
| Debt | ||||
Debt current | 10 | 407 | ||
Long-term debt | 5 | 442 | ||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (4,657) | 498 | ||
| Cash flow | ||||
Cash from operating activities | (5,632) | (5,605) | ||
CAPEX | (1) | |||
Cash from investing activities | ||||
Cash from financing activities | 3,146 | |||
FCF | (17,306) | (5,095) | ||
| Balance | ||||
Cash | 4,603 | 351 | ||
Long term investments | 69 | |||
Excess cash | 4,672 | 351 | ||
Stockholders' equity | (21,284) | (9,296) | ||
Invested Capital | 25,688 | 9,191 | ||
ROIC | ||||
ROCE | 5,089.08% | |||
| EV | ||||
Common stock shares outstanding | 18,566 | 14,745 | ||
Price | 1.05 | |||
Market cap | 19,494 | |||
EV | 14,838 | |||
EBITDA | (16,320) | (5,344) | ||
EV/EBITDA | ||||
Interest | 3,456 | 10 | ||
Interest/NOPBT | ||||